Liver Cancer and Potential Therapeutic Targets

Dear colleagues,

Primary liver cancer, mainly consisting of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, is a leading cause of cancer death worldwide. Recent advances in the development of multikinase inhibitors for the treatment of liver cancer brought us closer than ever to enabling the control or even cure of liver cancer with systemic therapy. However, therapeutic options and efficacy have not sufficiently met clinical demands yet. Furthermore, although prevalent mutations and affected pathways in the course of liver cancer development and progression have been identified, these have not led to therapeutic innovation. Therefore, in order to develop more efficient drugs or to improve current therapies, it is necessary to deepen our understanding of molecular mechanisms underlying liver cancer, and to identify previously unrecognized potential therapeutic targets.

This special issue covers research on molecular mechanisms underlying the development and progression of liver cancer from the viewpoints of diagnosis, prevention and/or therapy. Studies examining the therapeutic efficacy of molecular-targeted drugs or novel therapeutic approaches are also welcomed.

Dr. Hiroyuki Tsuchiya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.